Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 16/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573079 | 0.85 | HSD11B1 (0.42) | HSD11B1RXRANR1H2NR1H3 | |
| SCHEMBL15453343 | 0.84 | HSD11B1 (0.42) | HSD11B1PTGS2RXRANR1H2NR1H3 | |
| SCHEMBL3579162 | 0.84 | RXRA (0.51) | HSD11B1PTGS2RXRANR1H2NR1H3 | |
| SCHEMBL3576966 | 0.83 | PTGS2 (0.41) | HSD11B1PTGS2RXRANR1H2NR1H3 | |
| SCHEMBL3589436 | 0.83 | PTGS2 (0.46) | HSD11B1PTGS2RXRANR1H2NR1H3 | |
| SCHEMBL3579090 | 0.82 | RXRA (0.52) | HSD11B1PTGS2RXRANR1H2NR1H3 | |
| SCHEMBL3577242 | 0.81 | RXRA (0.42) | HSD11B1PTGS2RXRANR1H2NR1H3 | |
| SCHEMBL3583253 | 0.81 | RXRA (0.48) | HSD11B1PTGS2RXRANR1H2NR1H3 | |
| SCHEMBL3586677 | 0.80 | HSD11B1 (0.42) | HSD11B1PTGS2RXRANR1H2NR1H3 | |
| SCHEMBL3583401 | 0.80 | RXRA (0.55) | HSD11B1PTGS2RXRANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | NR1H2, NR1H3, NR1I2 | HSD11B1 161/4885PTGS2 400/4885RXRA 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.